1-(9-Methyl-3,9-diazaspiro[5.5]undecan-3-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 1-(9-Methyl-3,9-diazaspiro[5.5]undecan-3-yl)ethanone
• 英文别名: 1-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)ethanone
• 化学式: C₁₂H₂₂N₂O
• 分子量: 210.32
• InChiKey: JKJHITIBNOWSNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE<br/>[FR] NOUVEAUX COMPOSÉS D'IMIDAZOPYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS D'INDOLÉAMINE 2,3-DIOXYGÉNASE ET/OU DE TRYPTOPHANE-2,3-DIOXYGÉNASE
  申请人：IOMET PHARMA LTD

  公开号：WO2017189386A1

  公开（公告）日：2017-11-02

  Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

  本发明公开了式(I)的取代咪唑并吡啶化合物，其为吲哚胺2,3-双加氧酶(IDO)和/或色氨酸-2,3-双加氧酶(TDO)酶的抑制剂：(I)。还公开了这些化合物在潜在治疗或预防与IDO和/或TDO相关的疾病或障碍中的用途。还公开了包含这些化合物的组合物。进一步公开了这些组合物在潜在治疗或预防与IDO和/或TDO相关的疾病或障碍中的用途。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：TESARO INC

  公开号：WO2018136887A1

  公开（公告）日：2018-07-26

  Compounds of formula (IA) and formula (IB), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.

  提供了式(IA)和式(IB)的化合物，这些化合物作为吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶的抑制剂具有用途。还提供了包含这些化合物的药物组合物、套件以及与这些化合物相关的方法和用途。
• [EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE 1 (IRAK)/TYROSINE KINASE DU RÉCEPTEUR DE TYPE FMS (FLT3), LEURS PRODUITS PHARMACEUTIQUES ET LEURS PROCÉDÉS
  申请人：PHARMABLOCK SCIENCES NANJING INC

  公开号：WO2021159993A1

  公开（公告）日：2021-08-19

  Inhibitors of interleukin-1 receptor associated kinase (IRAK) enzyme/FMS-like receptor tyrosine kinase (FLT3) with Formula (I), a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. In Formula (I), X, X 1, X 2 is selected from N and C; and U, V and W groups are independently of each other a non-hydrogen monovalent group. Pharmaceutical products comprising the IRAK inhibitors and prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, and proliferative diseases, among others, are also provided. The interleukin-1 receptor associated kinase (IRAK) mentioned above can be IRAK4.

  具有公式（I）的白细胞介素-1受体相关激酶（IRAK）酶/类FMS受体酪氨酸激酶（FLT3）的抑制剂，其为药用可接受的盐、酯、前药、复合物、溶剂化物、水合物或其异构体，在任何晶体形式或非晶形式中。在公式（I）中，X、X1、X2从N和C中选择；U、V和W基团是非氢单价基团，彼此独立。还提供了包括IRAK抑制剂的药物产品以及预防和/或治疗炎症性疾病、自身免疫性疾病和增殖性疾病等。上述提到的白细胞介素-1受体相关激酶（IRAK）可以是IRAK4。
• NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE
  申请人：Iomet Pharma Ltd.

  公开号：EP3448522B1

  公开（公告）日：2021-01-20
• NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE
  申请人：Nishitani Yasuhiro

  公开号：US20140088302A1

  公开（公告）日：2014-03-27

  The present invention provides a novel compound which has a wide antimicrobial spectrum, and in particular exhibits potent antimicrobial activity against beta-lactamase producing Gram negative bacteria. Specifically, the present invention provides a compound of the formula (I): wherein each symbol is as defined in the specification, or an amino-protected compound when the amino group is present on the ring in the 7-side chain, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.